Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 30-Sep-2017

Cogentis Therapeutics, Inc.


Cogentis is a pre-clinical stage biotechnology company dedicated to developing therapies that target the dysregulated cyclin-dependent kinase 5 (CDK5) molecular pathway. Our vision is to lead the world in providing disease-modifying treatments capable of halting or reversing neurodegenerative conditions such as frontotemporal dementia (FTD) and Alzheimer’s disease (AD).


Original YouTube URL: Open

Introduction Video

Additional Questions

Who is your customer?


What problem does this idea/product solve or what market need does it serve?

Unprecedented approach to a validated target in Alzheimer's.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

The specificity of this drug for its target and the safety of preserving normal enzyme function (rather than inhibiting it) is attractive. The upstream nature of this intervention with compelling preclinical data is also attractive.

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

- Our team has the most experience in developing peptides - particularly targeting neurodegenerative diseases. - Our patented technology explores an entirely novel pharmacological approach to kinase biology. - Our parallel development plans for biomarkers and related but different indications provides ample flexibility for maximum ROI.